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Abstract
Background: Preventive drugs require long-term trials to show their effectiveness or harms and often a
lot of changes occur during post-marketing studies. The purpose of this article is to describe the research
process in a long-term randomized controlled trial and discuss the impact and consequences of changes
in the research environment.
Methods: The Estonian Postmenopausal Hormone Therapy trial (EPHT), originally planned to continue
for five years, was planned in co-operation with the Women's International Study of Long-Duration
Oestrogen after Menopause (WISDOM) in the UK. In addition to health outcomes, EPHT was specifically
designed to study the impact of postmenopausal hormone therapy (HT) on health services utilization.
Results: After EPHT recruited in 1999–2001 the Women's Health Initiative (WHI) in the USA decided
to stop the estrogen-progestin trial after a mean of 5.2 years in July 2002 because of increased risk of
breast cancer and later in 2004 the estrogen-only trial because HT increased the risk of stroke, decreased
the risk of hip fracture, and did not affect coronary heart disease incidence. WISDOM was halted in
autumn 2002. These decisions had a major influence on EPHT.
Conclusion: Changes in Estonian society challenged EPHT to find a balance between the needs of
achieving responses to the trial aims with a limited budget and simultaneously maintaining the safety of trial
participants. Flexibility was the main key for success. Rapid changes are not limited only to transiting
societies but are true also in developed countries and the risk must be included in planning all long-term
trials.
The role of ethical and data monitoring committees in situations with emerging new data from other 
studies needs specification. Longer funding for preventive trials and more flexibility in budgeting are 
mandatory. Who should prove the effectiveness of an (old) drug for a new preventive indication? In 
preventive drug trials companies may donate drugs but they take a financial risk, especially with licensed 
drugs. Public funding is crucial to avoid commercial biases. Legislation to share the costs of large post-
marketing trials as well as regulation of manufacturer's participation is needed. [ISRCTN35338757]
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Background
The importance of the trial process
Preventive medications require long-term trials to show
their effectiveness and harms. Carrying out a trial of long
duration is demanding for the researchers. Very few
reports have described the long-term trial process in prac-
tice [1,2]. When trial processes are not described publicly,
useful knowledge fails to accumulate. Especially for trials
that are unable to meet their targets, information about
the process is important to aid other researchers in antici-
pating and avoiding similar problems. Also, trials that
have successfully coped with unanticipated difficulties
should report their success stories.
Previous studies of the process of preventive trials have
mainly concentrated on the recruitment process [1,3-5],
failures in recruitment [6], the non-medical intervention
effect on compliance [7,8], and randomization [9]. Oak-
ley et al. [1,2] have reported a trial process on social sup-
port in motherhood and on peer-led sex education. They
found that an evaluation of the process was integral to
understand the outcomes. In a trial on the delivery of very
low birth weight infants, Lumley et al. [9] failed to achieve
randomization because of a critical shift in obstetric prac-
tice. In Finland the pilot for a non-blind, patient-managed
trial on hormone therapy (HT) revealed several obstacles
to the main trial, including the difficulty to discontinue
HT and a negative attitude among Finnish physicians
towards the trial [5].
We have found no process description of a successful trial
involving preventive drug therapy. To run a trial over
many years involves a significant risk that obstacles will
emerge. The purpose of this article is to describe the
research process in a long-term randomized controlled
trial, the Estonian Postmenopausal Hormone Therapy
trial (EPHT), and to discuss the impact and consequences
of changes in the research environment. We hope that this
report of the EPHT trial process would provide researchers
with valuable information for planning and carrying out
long-term trials.
Methods
The EPHT trial
The EPHT trial aimed to study the impact of postmeno-
pausal hormone therapy (HT) on diseases, subjective
well-being, social effects, health service utilization and
health care costs. Furthermore, we aimed to study the
impact of blinding on trial process and outcomes. In
regard to the long-term health effects, the aim was to study
whether HT increases the risk of cancers, and decreases the
risk of heart and cardiovascular diseases, fractures and
metabolic diseases. Because the EPHT alone did not have
power enough to detect HT effects on diseases, these out-
comes were planned to be pooled with the Women's
International Study of Long-Duration Oestrogen after
Menopause (WISDOM) to increase its power. The inde-
pendent aims of the EPHT trial were to study whether HT
increases women's well-being and decreases the preva-
lence of their symptoms, how HT affects experience of the
climacteric and ageing, and partner relationship. The
EPHT was specifically designed to investigate whether HT
increases health services utilization and therefore the non-
blind sub-trial was needed, which also made possible to
study methodological questions like the effect of blinding
on recruitment and trial results.
A pilot showed that doing a trial on HT in Finland was
unlikely to succeed due to women's and physicians' strong
preferences to HT [5], and it was decided to carry out the
trial (EPHT trial) in Estonia. Originally we had planned to
do our trial in close co-operation with WISDOM. In the
mid-1990s, the UK-based WISDOM unsuccessfully
sought financing from the European Union (EU) for a
large European HT study [10]. The UK Medical Research
Council (MRC) decided to finance the trial covering the
UK, Australia, and New Zealand. In view of this decision,
we planned our trial as an independent study, though still
working closely with WISDOM.
The planning of the trial was started in 1995. It was a four-
arm randomized controlled preventive trial on HT, origi-
nally planned for five years exposure, consisting of a blind
and a non-blind sub-study (Figure 1). The blind sub-study
represents a traditional randomized, double-blind, pla-
cebo-controlled trial except for the early randomization
prior to informed consent, whereas, the non-blind sub-
study was a randomized controlled trial with an open-
label HT arm and a non-treatment arm. For details of the
trial design and methods, see [11].
Participants were recruited using a postal questionnaire to
establish eligibility and to ask whether they wished to par-
ticipate in the trial. Those positive and potentially eligible
women were randomized to the four trial arms. Women
were mailed a letter briefly describing either the blind or
non-blind sub-study to which they had been randomized
and inviting them to the recruitment examination in one
of the study clinics. [12] The EPHT trial had three study
centers, two women's clinics in Tallinn, the capital of Esto-
nia, and a university women's clinic in Tartu, southern
Estonia. Trial staff in each study centre consisted of 2–3
gynaecologists and two midwives in each clinic, 13 alto-
gether.
Local coordination in Estonia was at the Institute of
Experimental and Clinical Medicine (EKMI, later the
National Institute for Health Development, TAI). In 1998
the trial received a positive statement from the Tallinn
Committee of Medical Ethics, and the trial was registeredBMC Medical Research Methodology 2008, 8:51 http://www.biomedcentral.com/1471-2288/8/51
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at the State Agency of Medicines in the same year. By
agreement drugs were to be donated by Wyeth, a US-
based pharmaceutical company, to the EPHT trial via the
WISDOM trial in the UK.
The trial drug was licensed in the USA and was a com-
bined regimen of conjugated equine oestrogens 0.625 mg
(CEE) and medroxyprogesterone acetate 2.5 mg (MPA). A
similar drug with a higher MPA dose (10 mg) had already
been licensed in Estonia. Women were to visit the study
clinics semi-annually to collect their trial medication, and
annually for an examination by the study physician; this
did not apply to women in the no-treatment-arm in the
non-blind sub-study, who were to visit only if needed.
Financing for the trial came from public sources such as
the Academy of Finland, STAKES, the Finnish Ministry of
Education, and the Estonian Ministry of Education and
Science, while the Universities of Tartu (Estonia) and
Tampere (Finland) and the Estonian National Institute for
Recruitment flow Figure 1
Recruitment flow.
Postmenopausal women aged 50-64 years. Postal questionnaire 
including trial introduction, invitation to participate 
(n=39 713) 
Wants to participate 
(n=6 605) 
Randomization (n=4 295) 
(Blind: HT or Placebo, Non-blind: HT or Non-treatment) 
Invited to examination 
Blind sub-study 
(n=2 136) 
Invited to examination 
Non-blind sub-study 
(n=2 159) 
Included
Blind HT 
(n=415)
Included
No treatment 
(n=524)
Included
Non-blind HT 
(n=503)
Included
Blind Placebo 
(n=381)
Found ineligible 
Found ineligible 
No examination visit
No informed consent
Found ineligible 
No examination visit
No informed consent
No response, wrong address, 
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Health Development (TAI, previously EKMI) offered insti-
tutional support.
Results
Impact of other studies on EPHT
Recruiting occurred from 1999–2001 (Figure 2) and 1823
women joined up. Half a year after recruiting was com-
pleted (July 2002), the Women's Health Initiative (WHI)
prematurely published its results in the USA. This had a
big influence on our trial, both directly and through its
impact on WISDOM. Originally we had calculated that
our trial exposure would have been completed before the
WHI is ready. The WHI was initiated in 1992 with a
planned completion date of 2007. It included two large
trials to investigate the effects of HT on the morbidity and
mortality of postmenopausal women aged 50 to 79.
Between 1993 and 1998, the WHI randomized 16 608
women with a uterus to the estrogen plus progestin trial
[13] and 10 739 women without uterus to the estrogen
only trial [14] to be treated for an average follow-up of 8.5
years [13].
Already in 2000 and 2001, the WHI Data and Safety Mon-
itoring Board recommended that the participating women
should be informed that the original hypothesis of cardi-
ovascular protection was no longer likely, but that the trial
would continue because the balance of risks and benefits
remained uncertain. In July 2002, the WHI estrogen-pro-
gestin trial was stopped because the breast cancer risk
comparison exceeded the pre-defined limits and the over-
all risks were seen to exceed the benefits as measured by
the global disease index [13]. By summer 2003, results in
several articles emerging from the WHI trial showed that
HT is not safe for disease prevention [13,15-17]. The trial
with estrogen alone continued until early 2004 when the
intervention was withdrawn because the original hypoth-
esis of estrogen preventing the risk of cardiovascular dis-
eases was unlikely [14].
The first time we became aware of the WHI warnings to its
trial participants was in 2001. The Trial Steering Commit-
tee kept itself updated via the WHI web site where we
learnt that a warning had been given also in 2000. We
tried to get further information with direct contacts, but
were not successful. We had no reason to send further
information to the EPHT trial women in 2001, because
the original written information at recruitment had stated
that "HT probably decreases cardiovascular diseases
(CVD), and estrogen is thought to have specific effects on
blood coagulation and plasma lipid concentration, but
their effect on CVD is still not clear. It is assumed that HT
decreases the risk of myocardial infarction, but it may
increase the risk of thrombosis for some women."
The EPHT Trial Steering Committee had its meeting in
September 2002 and unanimously decided to continue
the trial unless WISDOM discontinued for ethical reasons.
During the discussion it was suggested to open the blind-
ness in the blind sub-study and continue EPHT as a totally
non-blind trial, but that was not supported. We were sat-
isfied with the way the recruitment letter described the
uncertainties of HT effects. Thus, we did not change the
protocol in 2002.
By autumn 2002, WISDOM had recruited 5 700 women.
After WHI prematurely stopped its first trial in July 2002,
WISDOM's Data Monitoring and Ethics Committee rec-
ommended WISDOM to continue as long as women were
informed of the current state of knowledge. Likewise, the
Trial Steering Committee recommended continuation as
they found no strong scientific or ethical reasons to stop.
However, the Medical Research Council (MRC), who were
the main funding agency, decided to convene an Inde-
pendent International Committee to review the WHI find-
ings, the progress of WISDOM and other evidence. The
Committee concluded that "WISDOM was unlikely to
provide substantial evidence to influence clinical practice
in the next 10 years" [10]. MRC decided in October 2002
to stop the funding of WISDOM on the basis of the lack of
importance [18].
The halting of WISDOM in October 2002 did not have an
immediate effect on the continuation of our trial. In
November 2002 the EPHT Data Monitoring Committee
(DMC) made the annual interim analysis of the data and
found no results that would have demanded cessation of
the trial. A strong argument for us to continue the expo-
sure was the WISDOM Steering Committee's recommen-
dation to continue WISDOM. An important reason
behind the MRC decision to stop WISDOM was financial
rather than safety concerns. We wanted to obtain data to
answer our research questions other than effects on dis-
eases. However, as the WHI results suggested that breast
cancer risk increased by the length of exposure, the EPHT
Trial Steering Committee decided to shorten the trial
treatment to four years from the original five for those
women who had not yet been in the study for 4 years
(December 2002).
We kept the trial physicians and midwives informed
about all new results in other trials via information letters
and personal discussions. Also, the Tallinn Medical
Research Ethics Committee was regularly informed with
updated information from other HT trials. The participat-
ing women were kept up to date on the results of other tri-
als and their influence on EPHT as well as with the process
of the EPHT trial with an annual newsletter in Estonian. In
September 2002 women were told why WHI estrogen-
progestin trial was stopped, and were given the diseaseBMC Medical Research Methodology 2008, 8:51 http://www.biomedcentral.com/1471-2288/8/51
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Time flow of the trial Figure 2
Time flow of the trial.
EPHT Year Other trials 
         
Recruitment starts  1999  
         
        WISDOM recruitment starts 
         
 2000  
Mammogram screening starts        WHI warns 1 
         
         
 2001  
        WHI warns 2 
         
Recruitment ends         
 2002  
        WHI CEE+MPA exposure ends 
Decision I to shorten exposure        WISDOM recruitment stops 
Application to Wyeth        WISDOM exposure ends 
 2003  
         
Decision II to shorten exposure         
Decision to end exposure         
 2004  
Exposure ends        WHI CEE exposure ends 
         
         
 2005  BMC Medical Research Methodology 2008, 8:51 http://www.biomedcentral.com/1471-2288/8/51
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outcomes per 10 000 women for those using or not using
HT. Women were told that they had been in the trial for a
shorter period than women in the WHI, and women with
less than four years of exposure were encouraged to con-
tinue the trial treatment. We encouraged the women to
contact the researchers if they wanted more information.
In spite of all the given information no decrease in adher-
ence was detected, and only a few women had contacted
the trial staff because of the new warnings. The media cov-
erage of the 2002 results of the WHI estrogen-progestin
trial was very low and did not raise any public discussion
in Estonia. Instead, in Finland the WHI results were
widely discussed both in the professional and lay press
[19]. EPHT investigators in Finland were interviewed and
they explained that the WHI results should result in
decreasing long-term HT use. Many leading Finnish
gynaecologists belittled the significance of the WHI results
with various arguments [19].
In August 2003, following the release of the WHI results
of HT effects on dementia, cognitive functions, and qual-
ity of life [15,17,20], and the results from the Million
Women Study on HT effects on breast cancer [21], the
Trial Steering Committee shortened the exposure in our
trial for the second time. The exposure was shortened to
three years for women who had by that time received it for
less than three years.
In December 2003, our trial DMC had its annual meeting
where all cumulative information about other HT studies
were presented, as well as the results of the interim analy-
sis of the EPHT data. EPHT data showed an unfavourable
effect of HT on CVD, but not statistically significant. The
DMC had no pre-defined rules on how to interpret data
from other trials, but decided to recommend ceasing the
trial treatment, as results from other trials were against the
preventive use of HT. Based on the DMC recommenda-
tions, the Trial Steering Committee stopped the treatment
over a period up until May 31st 2004 to enable a final
medical examination to all women. As a result, 597
women received trial treatment at least for four full years,
808 for three years, and the rest 418 at least for two years
(Table 1).
Our trial received its drugs from Wyeth via WISDOM.
After WISDOM was discontinued, we sent Wyeth an
application for registration in their trial registry to receive
more drugs. However, the registration was never finalized:
during the lengthy negotiations, we had twice shortened
the trial, and in the end no more drugs were needed.
Besides abbreviating the trial duration, the new informa-
tion coming out from other trials led to a lot of additional
work: we had to thoroughly analyze the data and consider
its impact on our study protocol, to inform both women
and the clinical staff, as well as to monitor news reports.
Changes in research environment
Between the initial planning year (1995) and the halting
of the intervention (2004), Estonian society changed very
rapidly. Estonia had been a part of the Soviet Union with
a planned economy up until 1991, when the independent
Estonia had adopted a liberal market economy. By 1994–
95 pharmacies had been privatized and the availability of
drugs was no longer a problem and medicine choices were
determined mostly by prescribers [22]. In 2004 Estonia
became a member of the European Union and its eco-
nomic and scientific contacts with Western Europe
increased and income had increased, but less for poor
people [23]. A better financial situation and availability of
HT offered women in the blind sub-study and non-blind
control arm a possibility to buy HT.
In the early 1990s, Estonia was still a maiden country for
conducting a trial with HT. HT use did increase in the
1990s, but by 2000 it was still notably lower than in Fin-
land [24]. In an Estonian survey in 1998, only 4% of
women aged 45–64 reported current use of HT [25] com-
pared to 34% in Finland in 2000 [26].
By the mid-1990s, prices and salaries in Estonia were
lower than in most Western European countries, but the
infrastructure (including health services) was good and
western-style legislation and regulations had been devel-
Table 1: Numbers of women by the length of exposure (years) at the time of stopping exposure in the EPHT trial (May 2004).
Sub-study Arm Length of exposure (years)
2–2.9 3–3.9 4+ Total
Blind Hormone therapy 89 198 128 415
Placebo 85 182 114 381
Non-blind Open-label hormone therapy 127 212 164 503
Control 117 216 191 524
Total 418 808 597 1823BMC Medical Research Methodology 2008, 8:51 http://www.biomedcentral.com/1471-2288/8/51
Page 7 of 10
(page number not for citation purposes)
oped [27]. The Estonian Health Insurance Fund Database,
the Estonian Cancer Registry and the Estonian Mortality
Database made it possible to collect information about
women's health and health services use. The Estonian
Health Insurance Fund Database is unique and includes
information on all health care visits, diagnosis and pre-
scriptions [28].
Various changes in legislation, relevant institutions, and
financing occurred during our trial. The local co-ordinat-
ing centre, the Institute of Experimental and Clinical Med-
icine (EKMI), was also reorganized and it became the
National Institute for Health Development (TAI) as of
May 2003. Our study clinics were financed by the Esto-
nian Sickness Insurance Fund (later Health Insurance
Fund) [29]. Women's health outcomes were abstracted for
the EPHT trial from the Health Insurance Fund register.
Changes in the administration of the Health Insurance
Fund required us to conduct several negotiations to
ensure continuation of the trial. Women's recruitment vis-
its were classified as health check-up visits and they were
recorded in the Health Insurance Register.
During the trial some unexpected expenses occurred
(increase in salaries, payment for physicians, reimburse-
ment of mammograms for participants, etc) and prices
increased much faster than could have been expected at
the time of planning. During the trial period salaries rose
about 30%, which tightened the trial budget, which had
been planned in 1997. Originally only midwives were to
be paid and physicians were to be compensated by com-
modities like international medical journal subscription
or participation in international congresses. This turned
out to be impractical and physicians received compensa-
tion per recruited woman.
While Estonia has good health registries, at the planning
phase of the EPHT, Finland had better developed practices
in data protection than Estonia and so these were adapted
to our trial. During our trial, various changes were made
to the Estonian data protection laws that led to reduced
access to various registries. The 1996 Data Protection Law,
or its updated 2003 version, were not clear in regard to the
use of registries for research [30], with the ambiguity in
interpretations causing additional work and delays in
obtaining outcome data. A rapid turnover of personnel in
the ministries reduced experience in data protection prac-
tices. The trial participants had signed informed consent
permitting their survey and health examination data to be
linked with health registries, but the completeness of reg-
istries became a problem because the data protection
authority challenged the updating of these registers. Fur-
thermore, maintaining up-to-date addresses for the partic-
ipating women who had moved residence became
difficult, because we were not allowed to check addresses
from the population registry.
Data collection for disease outcomes in our trial was
mainly based on registries, and new and changing regula-
tions meant extra negotiations and time delays. Neverthe-
less, after difficult negotiations within the ministries all
necessary data other than deaths had been obtained up to
the end of 2004 as planned.
At the start of the recruitment in 1999, screening for breast
cancer with mammography was not in use in Estonia, not
even among HT users. If a woman had breast problems
she was referred to a mammologist, a specialized physi-
cian. To compensate for the missing screening program
we advised our study women to regularly palpate their
breasts through the Mama breast self-examination pro-
gram [31]. However, beginning in 2000, mammogram
screening in Estonia was gradually introduced. This devel-
opment – in addition to the advice given by local mam-
mologists – led us to add mammogram screening for all
trial women who had already been in the trial for two
years (Figure 2). Those women who were eligible for local
free of charge mammogram mass-screening programs
were encouraged to use the service. For others the costs
were covered by the trial, and they were unexpectedly
high.
Many foreign drug companies were interested in Estonia
and the number of approved clinical trials increased from
five in 1992 to over 80 in 2004 [32]. With the increasing
number of trials, we had to ensure that the women partic-
ipating in our study were not recruited to other trials. This
could effect EPHT results or reveal treatment medication
to women in the blind sub-trial.
Using a licensed regimen
The estrogen used in our study (CEE) had been available
since the 1940s [33] and combined estrogen-progestin
since the 1970s [34]. A wide variety of preparations have
been available for climacteric women [35]. When we
started our trial, HT was already available and in use in
Estonia, including the specific trial regimen.
Studying an established therapy had its advantages and
disadvantages. An advantage is that the ethical burden is
lessened because women outside the study can be freely
prescribed the drug. A disadvantage is that compliance in
the non-treatment arm can be easily compromised
through purchase of the drug outside the study. This was
not a major issue in our trial: only some women receiving
the placebo and less than 10% in the non-treatment arm
had been subsequently prescribed HT by the exposure end
[36].BMC Medical Research Methodology 2008, 8:51 http://www.biomedcentral.com/1471-2288/8/51
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The WHI researchers had chosen conjugated equine estro-
gens (CEE), which is the most widely prescribed prepara-
tion in the USA, but rarely used in Europe. WISDOM
approached major HT manufacturers, but Wyeth was the
only company prepared to supply drugs and matched pla-
cebos [10]. So, both the WHI and WISDOM ended up
studying the same type of HT out of the dozens of prepa-
rations available.
As a consequence, most health data now available in rela-
tion to long-term HT use are based on one type of drug
and, for example, transdermal preparations remain
untested over the long-term. Before the start of the WHI
and WISDOM, the applicability of specific HT prepara-
tions or formulations was not questioned [10], but later
proponents of preventive HT have used the specific fea-
tures of CEE as one argument to support continued use
[19].
Views of women and physicians
According to the EPHT pilot survey (n = 2 000, response
rate 69%) 53% of the women were of the opinion that the
climacteric is a normal phase in a woman's life which does
not need medical treatment and only 17% disagreed [25].
Few women were familiar with HT, 11% had ever used HT
and only 6% of the women supported HT for all postmen-
opausal women [25]. Women's inexperience and hesita-
tion in regard to HT may have contributed to the low
adherence in the placebo and HT-arms in the trial [36].
On the contrary, according to our survey in 2000, Esto-
nian gynaecologists favoured HT and 37% recommended
HT for postmenopausal women in climacteric [37]. GPs
referred almost all of their patients with menopausal
symptoms to a gynaecologist. Physicians thought that the
increase in the use of HT in Estonia was more based on
changes in physicians' opinions than that of women.
Gynaecologists had frequently participated in education
on HT, and education was often supported by industry
[24]. Trials can be considered as a means to increase drug
use, and this possibly contributed to physicians support-
ing our trial.
In preparing the information leaflets for women, it was
revealed that still in the 1990s many physicians had pater-
nalistic behaviours and that it was not considered crucial
to inform patients. Discussions about cancer risks still
seemed to be a taboo [24].
When we started our trial in Estonia, the culture of doing
clinical trials was still new. Compared to the pharmaceu-
tical companies, our resources were small, but due to the
strong local academic participation, we had been success-
ful in recruiting capable gynaecologists and midwives and
had only a small turnover of research personnel. As the
trial personnel had no prior epidemiological knowledge,
the trial co-ordinators organized free of charge semi-
annual seminars for the clinical staff on research method-
ology and controlled trials. In addition, when the local
research assistant visited the clinics to follow the recruit-
ment process and collect weekly summary sheets, she also
discussed the trial progress with the midwives, and offered
help in the case of problems. The trial staff and participat-
ing women could contact the trial co-ordinators any time
by phone and by mail, and the midwives at trial clinics
had special calling hours for trial participants. Trial partic-
ipants were mailed a personal birthday greeting through-
out the trial.
Practical issues
An application to the Estonian drug control authority for
permission was unproblematic. However, the first ship-
ment of drugs was in bulk and the Estonian law required
that the tablets have to be packed into vials and labelled
by a pharmaceutical company. Because of the small
number of tablets packing would have to be done by
hand, and many negotiations were needed before we
reached an agreement with a local pharmaceutical com-
pany. The next shipment of drugs was actually pre-packed,
with 215 tablets in each vial i.e. for seven months use, but
we still needed a pharmaceutical company to put the
labels on the vials. The company who had done the pack-
ing was unwilling to do it and we had to find a new com-
pany. More importantly, this changed the time of the
second and later visits: the six-month period between the
visits was changed to seven months.
In the EPHT trial, all the trial clinics were located in Esto-
nia, but the main scientific co-ordination was in Finland.
Health care was different between the two countries. Per-
sonal contacts and open discussions were most valuable
in bringing to light the different practices and in finding
solutions. Many external changes placed additional
demands especially on the local coordinator, who had to
seek new solutions and contacts.
Discussion and Conclusion
Keys for success
Treatment in the EPHT trial was stopped earlier than
planned, but the time was sufficient to provide answers to
our short-term research questions. Taking into account all
the outside changes occurring during the trial, we are sat-
isfied with the trial process. However, the low adherence
and the relatively short exposure time reduced the power
of the study. A very good collaboration between the Trial
Steering Committee, the Data Monitoring Committee, the
trial coordinators, and the trial clinics made it possible to
find a balance between the needs of achieving responses
to the trial aims with a limited budget and simultaneously
maintaining the safety of trial participants. Flexibility inBMC Medical Research Methodology 2008, 8:51 http://www.biomedcentral.com/1471-2288/8/51
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finding the best solutions in every situation was the main
key for success.
The relative success of the trial was due to keeping the trial
staff and participants continuously motivated as well as
tireless negotiations with authorities. Repeated changes in
the health care system and in legislation were keenly fol-
lowed up by appropriate actions (meetings with minis-
ters, data protection authorities, and other stakeholders,
articles in newspapers, discussions on radio). Preventive
drug trials usually have a long duration and the pressures
for changes to the protocol are strong. Our trial was a
small-scale trial which meant that it was easier to manage
in the face of such constantly changing circumstances: the
organization was flexible, while participants both in the
decision-making board and the clinics were fully commit-
ted to the trial. Rapid changes are currently possible in
every society and co-ordinator must be constantly aware
of the trial environment and identify possible threats
which can affect the trial process and be prepared to act in
case these changes occur.
Financing is a major challenge in a long-term preventive
trial. In the Finnish financing system, funding decisions
usually cover only a couple of years at a time, budgets are
often made on current prices and resources are bound to
budget years. More flexibility and longer commitment in
financing would help in administering a long-term trial.
In preventive drug trials the costs of drugs are usually
high. Even publicly funded researchers usually ask for
drugs to be donated from drug companies. Drug compa-
nies may not be so enthusiastic about sponsoring trials of
an established therapy, because it is a financial risk. Bene-
ficial results may increase sales, but not necessarily of the
specific product of the sponsoring company. If the results
are negative, pharmaceutical competitors may attempt to
deflect the impact by insisting the negative results apply
only to the drug used in the study. In the case of the WHI
and WISDOM, Wyeth Ayerst was the only pharmaceutical
company willing to take the risk. In 2001 Wyeth covered
70% of the global market [38]. When the non-beneficial
results from the WHI were released in June 2002 sales of
HT in the USA declined, with the decline in Wyeth prod-
ucts being especially dramatic [39-41]. Those companies
that did not take the risk of donating drugs to the trials
could now argue that their regimens are different from
Wyeth's and the trial results do not apply to their prod-
ucts.
An important question is who should prove the effective-
ness of an (old) drug for a new preventive indication. Pre-
ventive drug trials are often long-term, and usually need
large numbers of participants, thus increasing the costs
involved [42,43]. Public funding is crucial in maintaining
the independence of the trial from commercial biases. In
the future, some procedure to share the costs of large trials
should be negotiated where benefits and harms of
licensed drugs need to be (re)evaluated. Public support
for funding is needed for making evidence-based deci-
sions in health care. Also, amendments to legislation for
regulating the obligations of drug manufacturers to partic-
ipate in post-marketing studies are needed.
A big threat to long-term trials is new information from
other trials challenging the hypotheses and initial reason-
ing of the trial. In the case of WISDOM, a large-scale, well-
prepared trial was terminated in an early phase. The wis-
dom of that decision can be questioned, especially in the
light of the slow changes in the practice of HT use and the
current criticism of a lack of information. Many questions
about HT effects are still unanswered. However, there is
very little to be made to this extraneous threat to long-
term trials, besides reconsiderations of the norms used in
terminating trials. The role of ethical committees and of
data monitoring committees needs to be further specified
on how to interpret information from other studies and
make decisions about the pre-term stopping of trials.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
All authors have participated in designing the study. SLH
is the coordinating investigator; PV is the coordinator in
Estonia and EH is the director of the trial and MR is the
director of the trial in Estonia. SLH drafted the manuscript
and other authors commented and revised it. All authors
read and approved the final manuscript.
Acknowledgements
The trial was financially supported by The Academy of Finland (Grant 
number 69838 and 201490), STAKES, the Finnish Ministry of Education 
(Doctoral Programs in Public Health), and the Ministry of Education and 
Science in Estonia (target funding 01921112s02 and SF0940026s07), and the 
National Institute for Health Development in Estonia. The drugs were 
donated by Wyeth-Ayerst via the WISDOM trial (Women's International 
Study of Long Duration Estrogen after Menopause), coordinated by Dr. 
Madge Vickers, London, U.K. We express our sincere gratitude to the trial 
physicians, trial midwives and women who participated in the trial. We 
acknowledge the efforts of Helle Karro, Mare Tekkel, Lea Laaniste and 
Sigrid Vorobjov in conducting the trial.
References
1. Oakley A: Social support and motherhood. The natural his-
tory of a research project.  Oxford,  Blackwell; 1992. 
2. Oakley A, Strange V, Stephenson J, Forrest S, Monteiro H: Evaluat-
ing Processes: A Case Study of a Randomized Controlled
Trial of Sex Education.  Evaluation 2004, 10:440-462.
3. Oakley A, Rajan L, Grant A: Social support and pregnancy out-
come.  Br J Obstet Gynaecol 1990, 97:155-162.
4. Oakley A, Wiggins M, Turner H, Rajan L, Barker M: Including cul-
turally diverse samples in health research: a case study of an
urban trial of social support.  Ethn Health 2003, 8:29-39.BMC Medical Research Methodology 2008, 8:51 http://www.biomedcentral.com/1471-2288/8/51
Page 10 of 10
(page number not for citation purposes)
5. Hokkanen T, Hemminki E, Aalto P, Hakama M, Huhtala H, Jylhä M,
Karjalainen S, Tuimala R: Patient Managed Clinical Trial.  Control
Clin Trials 1997, 18:140-150.
6. Amir L, Lumley J, Garland S: A failed RCT to determine if antibi-
otics prevent mastitis: Cracked nipples colonized with Sta-
phylococcus aureus: A randomized treatment trial
[ISRCTN65289389].  BMC Pregnancy and Childbirth 2004, 4:19.
7. Campbell R, Evans M, Tucker M, Quilty B, Dieppe P, Donovan JL:
Why don't patients do their exercises? Understanding non-
compliance with physiotherapy in patients with osteoarthri-
tis of the knee.  J Epidemiol Commun H 2001, 55:132-138.
8. Moore L, Campbell R, Whelan A, Mills N, Lupton P, Misselbrook E,
Frohlich J: Self help smoking cessation in pregnancy: cluster
randomised controlled trial.  BMJ 2002, 325:1383.
9. Lumley J, Lester A, Renou P, Wood C: A failed RCT to determine
the best method of delivery for very low birth weight infants.
Control Clin Trials 1985, 6:120-127.
10. Vickers M, Meade T, Darbyshire J: WISDOM: history and early
demise - was it inevitable?  Climacteric 2002, 5:317-325.
11. Veerus P, Hovi SL, Fischer K, Rahu M, Hakama M, Hemminki E:
Results from the Estonian postmenopausal hormone ther-
apy trial [ISRCTN35338757].  Maturitas 2006, 55:162-173.
12. Hemminki E, Hovi SL, Veerus P, Sevon T, Tuimala R, Rahu M, Hakama
M: Blinding decreased recruitment in a prevention trial of
postmenopausal hormone therapy.  J Clin Epidemiol 2004,
57:1237-1243.
13. Writing Group for the Women's Health Initiative Investigators :
Risks and benefits of estrogen plus progestin in healthy post-
menopausal women: principal results From the Women's
Health Initiative randomized controlled trial.  JAMA 2002,
288:321-333.
14. The Women's Health Initiative Steering Committee : Effects of con-
jugated equine estrogen in postmenopausal women with
hysterectomy: the Women's Health Initiative randomized
controlled trial.  JAMA 2004, 291:1701-1712.
15. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK,
Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Was-
sertheil-Smoller S, Wactawski-Wende J: Estrogen plus progestin
and the incidence of dementia and mild cognitive impair-
ment in postmenopausal women: the Women's Health Initi-
ative Memory Study: a randomized controlled trial.  JAMA
2003, 289:2651-2662.
16. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Tre-
visan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong
ND, Crouse JR, Stein E, Cushman M: Estrogen plus progestin and
the risk of coronary heart disease.  N Engl J Med 2003,
349:523-534.
17. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL,
Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC,
Coker LH, Dailey M, Bowen D: Effect of estrogen plus progestin
on global cognitive function in postmenopausal women: the
Women's Health Initiative Memory Study: a randomized
controlled trial.  JAMA 2003, 289:2663-2672.
18. MRC stops study of long term use of HRT.  MRC press release:
October 23, 2002 2002:-.
19. Hemminki E: Opposition to unpopular research results: Finn-
ish professional reactions to the WHI findings.  Health Policy
2004, 69:283-291.
20. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JAE, Patterson
RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA,
Valanis BG, the Women's Health Initiative Investigators: Effects of
Estrogen plus Progestin on Health-Related Quality of Life.  N
Engl J Med 2003, 348:1839-1854.
21. Million Women Study Collaborators : Breast cancer and hor-
mone-replacement therapy in the Million Women Study.
Lancet 2003, 362:419-427.
22. Kiivet RA, Bergman U, Rootslane L, Rago L, Sjoqvist F: Drug use in
Estonia in 1994-1995: a follow-up from 1989 and comparison
with two Nordic countries.  Eur J Clin Pharmacol 1998, 54:119-124.
23. Rõõm T, Kallaste E: Naised-mehed Eesti tööturul: palgaerine-
vuste hinnang.  Poliitikaanalüüs 2004 [http://www.praxis.ee/data/
Palgaerinevus_veebi0.pdf].
24. Hemminki E, Karttunen T, Hovi SL, Karro H: The drug industry
and medical practice--the case of menopausal hormone
therapy in Estonia.  Soc Sci Med 2004, 58:89-97.
25. Hovi SL, Veerus P, Karro H, Topo P, Hemminki E: Women's views
of the climacteric at the time of low menopausal hormone
use, Estonia 1998.  Maturitas 2005, 51:413-425.
26. Topo P: Hormonikäytön väestöryhmittäiset erot.  In Vaihdevu-
osien hormonihoito - Miksi aihe puhuttaa? Vammala, Duodecim, Suomen
Akatemia; 2004:31-37. 
27. Rägo L: An update of regulatory affairs in Estonia: June 15-16;
Vilnius, Lithuania.  Volume NLN Publication No 49. Nordiska
läkemedelsnämnden; 1998:19-24. 
28. Veerus P, Fischer K, Hovi SL, Karro H, Hemminki E: Does hormone
replacement therapy affect the use of prescription medi-
cines in postmenopausal women: experience from the Esto-
nian Postmenopausal Hormone Therapy Trial
[ISRCTN35338757].  BJOG 2007, 114:548-554.
29. Jesse M, Habicht J, Aaviksoo A, Koppel A, Irs A, Thomson S: Health
care systems in transition: Estonia.  Copenhagen, WHO Regional
Office for Europe on behalf of the European Observatory on Health Sys-
tems and Policies; 2004  [http://www.euro.who.int/Document/
E85516.pdf].
30. Rahu M, McKee M: Epidemiological research labelled as a vio-
lation of privacy: the case of Estonia.  Int J Epidemiol 2008,
37:678-682.
31. Gästrin G: The Mama programme for breast cancer control.
In Department of Public Health Volume ser A 394. Tampere, University
of Tampere; 1994. 
32. State Agency of Medicines : Approved clinical trials in Estonia in
1992-2004.   2005 [http://www.sam.ee/1121].
33. Coney S: The menopause industry: how the medical establish-
ment exploits women.  Alameda CA, Hunter House; 1994. 
34. Wentz WB: Progestin therapy in endometrial hyperplasia.
Gynecol Oncol 1974, 2:362-367.
35. van Keep PA: The history and rationale of hormone replace-
ment therapy.  Maturitas 1990, 12:163-170.
36. Vorobjov S, Hovi SL, Veerus P, Pisarev H, Rahu M, Hemminki E:
Treatment adherence in the Estonian postmenopausal hor-
mone therapy (EPHT) trial [ISRCTN35338757].  Maturitas
2005, 52:286-295.
37. Hovi SL, Karttunen T, Karro H, Hemminki E: Comparison of Esto-
nian and Finnish physicians' opinions of menopause and hor-
mone therapy.  Maturitas 2004, 49:107-113.
38. Clark J: A hot flush for Big Pharma.  BMJ 2003, 327:400.
39. Hillman JJ, Zuckerman IH, Lee E: The Impact of the Women's
Health Initiative on Hormone Replacement Therapy in a
Medicaid Program.  J Womens Health 2004, 13:986-992.
40. Buist DSM, Newton KM, Miglioretti DL, Beverly K, Connelly MT,
Andrade S, Hartsfield CL, Wei F, Chan KA, Kessler L: Hormone
Therapy Prescribing Patterns in the United States.  Obstet
Gynecol 2004, 104:1042-1050.
41. Hersh AL, Stefanick ML, Stafford RS: National Use of Postmeno-
pausal Hormone Therapy: Annual Trends and Response to
Recent Evidence.  JAMA 2004, 291:47-53.
42. The Women's Health Initiative Study Group : Design of the
Women's Health Initiative Clinical Trial and Observational
Study.  Control Clin Trials 1998, 19:61-109.
43. The ATCB cancer prevention study group : The Alpha-Tocophe-
rol, Beta-Carotene lung cancer prevention study: Design,
methods, participant characteristics, and compliance.  AEP
1994, 4:1-10.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2288/8/51/prepub